GATM and neoplasm: O6-alkylguanine-DNA alkyltransferase activity in PBMCs has been used as a pharmacodynamic surrogate end point in several clinical studies of DNA-damaging agents, although changes in AGAT activity in PBMCs may not reflect changes in tumour tissues with some agents (Willson et al, 1995; Spiro et al, 1999).